



Development of mechanism-based femtomolar inhibitors with anticancer properties

Vipender Singh,

Investigator at Novartis Institute of Biomedical Research, USA

Abstract:

Enzymes are good targets for the design of anticancer drugs. For example, many kinases, epigenetic enzymes, post-translational modifying enzymes etc. have been targeted for developing anticancer drugs. Enzymes are biochemical catalysts that increase the rate of their reactions by stabilizing their transition states. The active sites of enzymes bind tightly, with sub-attomolar dissociation constants, to their transition states. Therefore, studying enzymatic transition states are important for developing tight binding therapeutics. Despite their usefulness in developing tight binding inhibitors, enzymatic transition state structures are difficult to obtain experimentally because they exist for less than a single bond vibration or less than a picosecond. In this work, we used experimental methods based on kinetic isotope effect and computational tools of quantum chemistry to obtain geometric and electrostatic structures of the transition state of enzymes implicated in head and neck, and lung cancers. We then used the transition state structures to develop a chemical library that incorporated the properties of the transition states. These drug candidates bound to the target enzymes with dissociation constants in the low femtomolar range. These drug candidates showed strong anticancer properties against the head and neck and lung cancers in rodent xenograft models. They are currently in clinical development.

References

1. Alkorta I, Elguero J, Liebman JF. 2006. The annular tautomerism of imidazoles and pyrazoles: the possible existence of nonaromatic forms. *Struct Chem* 17: 439–444.
2. Antonov L. 2014. Tautomerism—methods and theories. Wiley, New York.
3. Baker JW, Ingold CK, Thorpe JF. 1924. XXXVI.—Ring-chain tautomerism. Part IX. The mutarotation of the sugars. *J Chem Soc Trans* 125: 268–291.



4. Bakker JM, Compagnon I, Meijer G, von Helden G, Kabeláček M, Hobza P, de Vries MS. 2004. The mid-IR absorption spectrum of gas-phase clusters of the nucleobases guanine and cytosine. *Phys Chem Chem Phys* 6: 2810–2815.
5. Batey RT, Gilbert SD, Montange RK. 2004. Structure of a natural guanine-responsive riboswitch complexed with the metabolite hypoxanthine. *Nature* 432: 411–415.

[2nd Webinar on Molecular Science and Technology, November 06, 2020, London, UK](#)

Citation: Dr. Vipender Singh, Development of mechanism-based femtomolar inhibitors with anticancer properties, Webinar on Molecular Science and Technology, November 06, 2020